Comment on: Butler et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125

Diabetes Care. 2013 Dec;36(12):e213. doi: 10.2337/dc13-1134.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Animals
  • Humans
  • Incretins / therapeutic use*

Substances

  • Incretins